跳到正文
原文
MedPage Today·· 4 小时前精选AI 评分67

首个siRNA疗法获批用于治疗全身性重症肌无力

First siRNA Therapy Approved for Myasthenia Gravis

AI 导读

FDA批准了Cemdisiran(Livsayis)用于治疗抗乙酰胆碱受体抗体阳性成人全身性重症肌无力,这是首个获批的siRNA疗法。该药在24周的III期NIMBLE试验中显示显著改善患者日常生活活动能力。

推荐理由

原文明确给出批准事项与适用范围,读者可据此判断对同类产品的影响。

正文

— Cemdisiran is the second C5 inhibitor the FDA has authorized in a week

by Judy George, Deputy Managing Editor, MedPage Today

November 19, 2026 • 2 min read

The FDA approved subcutaneous cemdisiran (Livsayis), a small interfering RNA (siRNA) therapy, to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive, Regeneron announced Wednesday.

Cemdisiran targets complement component 5 (C5), inhibiting terminal complement activation, a key driver of AChR-positive myasthenia gravis. It is the first approved siRNA therapy for myasthenia gravis.

The drug is the second C5 inhibitor the FDA has authorized to treat myasthenia gravis in a week, following the agency's approval of gefurulimab (Klygefa) last Friday.

The approval of cemdisiran was based on data from the 24-week phase III NIMBLE trial. For the primary outcome, Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores improved from baseline by 4.5 points in the cemdisiran group versus 2.2 points in the placebo group, corresponding to an adjusted improvement of 2.3 points (P=0.0005). MG-ADL improvements were seen as early as 2 weeks after starting treatment.

A key secondary outcome showed a 4.2-point improvement in Quantitative Myasthenia Gravis (QMG) total scores at 24 weeks compared with a 1.5-point improvement with placebo, corresponding to an adjusted improvement of 2.8 points (P=0.0015).

The MG-ADL is a patient-reported measure of disease severity and functional impairment, with scores ranging from 0 to 24. The QMG is a physician-administered evaluation of muscle function, with scores ranging from 0 to 39.

In the NIMBLE trial, adverse events occurred in 69% of participants in the cemdisiran group and 77% in the placebo group. The most common adverse event in the cemdisiran group was upper respiratory tract infection (12%), which occurred at a similar rate in the placebo group (11%).

Serious adverse events were less frequent in the cemdisiran group (3%) than in the placebo group (14%). No serious or meningococcal infections were reported in the cemdisiran group.

No deaths were reported during the double-blind treatment period. Two deaths occurred afterward: one, due to pneumonia, was considered treatment-related by the investigator but not by the sponsor.

Cemdisiran is administered subcutaneously four times a year and is available only through a risk evaluation and mitigation strategy (REMS) program, Regeneron said.

The drug carries a boxed warning for serious and life-threatening infections caused by Neisseria meningitidis. Besides gefurulimab, three other C5 inhibitors have been approved by the FDA for myasthenia gravis: eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq). All carry a similar warning, and patients are required to comply with recommendations for meningococcal vaccinations.

People with generalized myasthenia gravis "experience profound muscle weakness that can affect how they talk, see, breathe and move, and with it their ability to carry out everyday activities," said Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America. "This approval is a positive milestone for the [generalized myasthenia gravis] community, reflecting continued progress on outcomes that matter most to patients."

来源:MedPage Today · medpagetoday.com